Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for KalVista Pharmaceuticals (KALV) over the last 10 years, with Q2 2025 value amounting to $234000.0.

  • KalVista Pharmaceuticals' Capital Expenditures rose 11869.16% to $234000.0 in Q2 2025 from the same period last year, while for Apr 2025 it was $499000.0, marking a year-over-year increase of 2443.89%. This contributed to the annual value of $495000.0 for FY2025, which is 2344.14% up from last year.
  • Per KalVista Pharmaceuticals' latest filing, its Capital Expenditures stood at $234000.0 for Q2 2025, which was up 11869.16% from $94000.0 recorded in Q4 2024.
  • Over the past 5 years, KalVista Pharmaceuticals' Capital Expenditures peaked at $234000.0 during Q2 2025, and registered a low of $6000.0 during Q3 2023.
  • Moreover, its 3-year median value for Capital Expenditures was $94000.0 (2024), whereas its average is $113285.7.
  • Over the last 5 years, KalVista Pharmaceuticals' Capital Expenditures had its largest YoY gain of 96666.67% in 2024, and its largest YoY loss of 5228.43% in 2024.
  • Quarter analysis of 3 years shows KalVista Pharmaceuticals' Capital Expenditures stood at $197000.0 in 2023, then tumbled by 52.28% to $94000.0 in 2024, then soared by 148.94% to $234000.0 in 2025.
  • Its Capital Expenditures stands at $234000.0 for Q2 2025, versus $94000.0 for Q4 2024 and $64000.0 for Q3 2024.